<p>Nuvation Bio Inc.（纽约证券交易所代码：NUVB - 获取免费报告）的股票在周二交易量强劲，此前该公司宣布季度收益超出预期。当天交易了 6,780,232 股，较前一交易日的 5,075,067 股增加了 34%。该股最后交易价格为$4.5760，之前收盘价为$5.17。</p>
<p>该公司报告季度每股收益（EPS）为（$0.16），超出市场共识预期的（$0.17）$0.01。该季度的收入为 1312 万美元，而分析师预期为 748 万美元。Nuvation Bio 的净利润率为负的 1413.43%，股本回报率为负的 46.14%。</p>
<h2>分析师评级调整</h2>
<p>几位股票分析师最近对 NUVB 股票发布了报告。Citizens Jmp 将 Nuvation Bio 的目标价从$6.00 上调至$8.00，并在周二的研究报告中给予该股 “市场表现优于大盘” 的评级。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了 Nuvation Bio 的 “卖出（d-）” 评级。Wall Street Zen 在 8 月 17 日的研究报告中将 Nuvation Bio 的评级从 “卖出” 上调至 “持有”。加拿大皇家银行在 8 月 8 日的研究报告中将 Nuvation Bio 的目标价从$6.00 上调至$7.00，并给予该股 “表现优于大盘” 的评级。最后，花旗集团在周二的研究报告中重申了 Nuvation Bio 的 “市场表现优于大盘” 评级。一位研究分析师给予该股 “强烈买入” 评级，七位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Nuvation Bio 目前的平均评级为 “适度买入”，共识目标价为$8.43。</p>
<p><strong>阅读我们对 Nuvation Bio 的最新分析</strong></p>
<h2>内部人士买卖</h2>
<p>在其他 Nuvation Bio 的新闻中，内部人士 Gary Hattersley 在 10 月 27 日（星期一）出售了 100,000 股该公司的股票。股票以平均价格$5.02 出售，总价值为$502,000.00。该交易已在证券交易委员会的备案中披露，您可以通过此链接访问。29.93% 的股票由公司内部人士持有。</p>
<h2>Nuvation Bio 的机构交易</h2>
<p>几位大型投资者最近增加或减少了对该公司的持股。Millennium Management LLC 在第一季度将其在 Nuvation Bio 的持股增加了 52.4%。Millennium Management LLC 目前拥有 3,774,003 股该公司的股票，价值$6,642,000，在此期间又购买了 1,298,131 股。Natixis 在第二季度获得了 Nuvation Bio 的新头寸，价值$1,766,000。Marshall Wace LLP 在第二季度获得了 Nuvation Bio 的新头寸，价值$1,699,000。Geode Capital Management LLC 在第二季度将其在 Nuvation Bio 的持股增加了 16.8%。Geode Capital Management LLC 目前拥有 5,994,798 股该公司的股票，价值$11,691,000，在上个季度又购买了 864,194 股。最后，AWM Investment Company Inc.在第一季度获得了 Nuvation Bio 的新头寸，价值$1,144,000。61.67% 的股票由机构投资者持有。</p>
<h2>Nuvation Bio 股价下跌 12.0%</h2>
<p>该股市值为 15.6 亿美元，市盈率为-7.15，贝塔系数为 1.48。该公司的 50 日移动平均线为$3.68，200 日移动平均线为$2.75。该公司的债务与股本比率为 0.13，速动比率为 9.38，流动比率为 9.39。</p>
<h2>Nuvation Bio 公司简介</h2>
<p>（获取免费报告）</p>
<p>Nuvation Bio Inc 是一家临床阶段的生物制药公司，专注于肿瘤治疗候选药物的开发。该公司的主要产品候选药物是 NUV-868，一种 BD2 选择性口服小分子 BET 抑制剂，能够表观遗传学调节控制肿瘤生长和分化的蛋白质，包括 c-myc 等癌基因；NUV-1156，一种 AR 结合剂 Xtandi，针对晚期前列腺癌，具有进入通常通过手术前列腺切除术治疗的早期阶段的潜力；以及药物 - 药物结合（DDC）平台，利用抗癌疗法药物结合类中的新型治疗方法，将抗癌药物输送到癌细胞，以及 NUV-1176，一种 PARP 抑制剂，针对 ER+ 乳腺癌和卵巢癌。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Nuvation Bio</li>
<li>成长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>英特尔的 SambaNova 计划不是收购，而是突袭</li>
<li>如何利用分析师评级进行交易</li>
<li>为什么 Roblox 股票在第三季度下跌后可能飙升 75%</li>
<li>关于 Markup 计算器</li>
<li>亚马逊与苹果：哪只 Mag 7 更值得购买？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资$1,000 在 Nuvation Bio 吗？</h2>
<p>在您考虑 Nuvation Bio 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Nuvation Bio 并不在名单上。</p>
<p>虽然 Nuvation Bio 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NUVB

<p>Nuvation Bio Inc.（纽约证券交易所代码：NUVB）在报告季度收益超出预期后，交易量激增，成交量达到 678 万股。该公司公布的每股收益为（$0.16），超出预期，收入为 1312 万美元，亦超出预期。分析师的评级各不相同，其中一位给予 “强烈买入”，七位给予 “买入”，一位给予 “卖出”。该股目前下跌 12%，市值为 15.6 亿美元。Nuvation Bio 专注于开发肿瘤治疗药物，包括其主要候选药物 NUV-868</p>

<p>Shares of Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) saw strong trading volume on Tuesday after the company announced better than expected quarterly earnings. 6,780,232 shares were traded during trading, an increase of 34% from the previous session's volume of 5,075,067 shares.The stock last traded at $4.5760 and had previously closed at $5.17.</p>
<div class="lb-trans"><p>Nuvation Bio Inc.（纽约证券交易所代码：NUVB - 获取免费报告）的股票在周二交易量强劲，此前该公司宣布季度收益超出预期。当天交易了 6,780,232 股，较前一交易日的 5,075,067 股增加了 34%。该股最后交易价格为$4.5760，之前收盘价为$5.17。</p>
</div><p>The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $13.12 million for the quarter, compared to analysts' expectations of $7.48 million. Nuvation Bio had a negative net margin of 1,413.43% and a negative return on equity of 46.14%.</p>
<div class="lb-trans"><p>该公司报告季度每股收益（EPS）为（$0.16），超出市场共识预期的（$0.17）$0.01。该季度的收入为 1312 万美元，而分析师预期为 748 万美元。Nuvation Bio 的净利润率为负的 1413.43%，股本回报率为负的 46.14%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>Several equities analysts have recently issued reports on NUVB shares. Citizens Jmp lifted their price objective on shares of Nuvation Bio from $6.00 to $8.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Tuesday. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Nuvation Bio in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Nuvation Bio from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, August 17th. Royal Bank Of Canada lifted their target price on shares of Nuvation Bio from $6.00 to $7.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, August 8th. Finally, Citigroup reaffirmed a &#34;market outperform&#34; rating on shares of Nuvation Bio in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Nuvation Bio presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $8.43.</p>
<div class="lb-trans"><p>几位股票分析师最近对 NUVB 股票发布了报告。Citizens Jmp 将 Nuvation Bio 的目标价从$6.00 上调至$8.00，并在周二的研究报告中给予该股 “市场表现优于大盘” 的评级。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了 Nuvation Bio 的 “卖出（d-）” 评级。Wall Street Zen 在 8 月 17 日的研究报告中将 Nuvation Bio 的评级从 “卖出” 上调至 “持有”。加拿大皇家银行在 8 月 8 日的研究报告中将 Nuvation Bio 的目标价从$6.00 上调至$7.00，并给予该股 “表现优于大盘” 的评级。最后，花旗集团在周二的研究报告中重申了 Nuvation Bio 的 “市场表现优于大盘” 评级。一位研究分析师给予该股 “强烈买入” 评级，七位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Nuvation Bio 目前的平均评级为 “适度买入”，共识目标价为$8.43。</p>
</div><p><strong>Read Our Latest Analysis on Nuvation Bio</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Nuvation Bio 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖</h2>
</div><p>In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of the business's stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $5.02, for a total value of $502,000.00. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. 29.93% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Nuvation Bio 的新闻中，内部人士 Gary Hattersley 在 10 月 27 日（星期一）出售了 100,000 股该公司的股票。股票以平均价格$5.02 出售，总价值为$502,000.00。该交易已在证券交易委员会的备案中披露，您可以通过此链接访问。29.93% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Nuvation Bio</h2>
<div class="lb-trans"><h2>Nuvation Bio 的机构交易</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its holdings in shares of Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company's stock worth $6,642,000 after buying an additional 1,298,131 shares during the period. Natixis acquired a new position in Nuvation Bio during the 2nd quarter valued at $1,766,000. Marshall Wace LLP acquired a new position in Nuvation Bio during the 2nd quarter valued at $1,699,000. Geode Capital Management LLC raised its stake in Nuvation Bio by 16.8% during the 2nd quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company's stock valued at $11,691,000 after purchasing an additional 864,194 shares during the last quarter. Finally, AWM Investment Company Inc. acquired a new position in Nuvation Bio during the 1st quarter valued at $1,144,000. 61.67% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几位大型投资者最近增加或减少了对该公司的持股。Millennium Management LLC 在第一季度将其在 Nuvation Bio 的持股增加了 52.4%。Millennium Management LLC 目前拥有 3,774,003 股该公司的股票，价值$6,642,000，在此期间又购买了 1,298,131 股。Natixis 在第二季度获得了 Nuvation Bio 的新头寸，价值$1,766,000。Marshall Wace LLP 在第二季度获得了 Nuvation Bio 的新头寸，价值$1,699,000。Geode Capital Management LLC 在第二季度将其在 Nuvation Bio 的持股增加了 16.8%。Geode Capital Management LLC 目前拥有 5,994,798 股该公司的股票，价值$11,691,000，在上个季度又购买了 864,194 股。最后，AWM Investment Company Inc.在第一季度获得了 Nuvation Bio 的新头寸，价值$1,144,000。61.67% 的股票由机构投资者持有。</p>
</div><h2>Nuvation Bio Trading Down 12.0%</h2>
<div class="lb-trans"><h2>Nuvation Bio 股价下跌 12.0%</h2>
</div><p>The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.15 and a beta of 1.48. The company's 50 day moving average is $3.68 and its 200 day moving average is $2.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.38 and a current ratio of 9.39.</p>
<div class="lb-trans"><p>该股市值为 15.6 亿美元，市盈率为-7.15，贝塔系数为 1.48。该公司的 50 日移动平均线为$3.68，200 日移动平均线为$2.75。该公司的债务与股本比率为 0.13，速动比率为 9.38，流动比率为 9.39。</p>
</div><h2>Nuvation Bio Company Profile</h2>
<div class="lb-trans"><h2>Nuvation Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.</p>
<div class="lb-trans"><p>Nuvation Bio Inc 是一家临床阶段的生物制药公司，专注于肿瘤治疗候选药物的开发。该公司的主要产品候选药物是 NUV-868，一种 BD2 选择性口服小分子 BET 抑制剂，能够表观遗传学调节控制肿瘤生长和分化的蛋白质，包括 c-myc 等癌基因；NUV-1156，一种 AR 结合剂 Xtandi，针对晚期前列腺癌，具有进入通常通过手术前列腺切除术治疗的早期阶段的潜力；以及药物 - 药物结合（DDC）平台，利用抗癌疗法药物结合类中的新型治疗方法，将抗癌药物输送到癌细胞，以及 NUV-1176，一种 PARP 抑制剂，针对 ER+ 乳腺癌和卵巢癌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Nuvation Bio</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>Intel's SambaNova Play Isn't an Acquisition, It's an Ambush</li>
<li>How to trade using analyst ratings</li>
<li>Why Roblox Stock Could Soar 75% After the Q3 Dip</li>
<li>About the Markup Calculator</li>
<li>Amazon vs. Apple: Which Mag 7 Is the Better Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Nuvation Bio</li>
<li>成长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>英特尔的 SambaNova 计划不是收购，而是突袭</li>
<li>如何利用分析师评级进行交易</li>
<li>为什么 Roblox 股票在第三季度下跌后可能飙升 75%</li>
<li>关于 Markup 计算器</li>
<li>亚马逊与苹果：哪只 Mag 7 更值得购买？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Nuvation Bio Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资$1,000 在 Nuvation Bio 吗？</h2>
</div><p>Before you consider Nuvation Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Nuvation Bio 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Nuvation Bio 并不在名单上。</p>
</div><p>While Nuvation Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Nuvation Bio 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nuvation Bio（NYSE:NUVB）因盈利超预期而交易量强劲